DDM-034 - Targeting the TSP1/ TXR1 axis with metronomic micellar docetaxel to overcome chemoresistance in triple-negative breast cancer

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: DDM-034
• By: GUAN, Yingyun (School of Pharmacy and Ruijin Hospital; Shanghai Jiaotong University, China)
• Co-author(s): Ms Yingyun Guan (School of Pharmacy and Ruijin Hospital; Shanghai Jiaotong University, Shanghai, China)
  Ms Wei Zhou (School of Pharmacy and Ruijin Hospital; Shanghai Jiaotong University, Shanghai, China)
  Dr Jinmei Jin (Shanghai University of Traditional Chinese Medicine, Shanghai, China)
  Prof Xin Luan (Shanghai University of Traditional Chinese Medicine, Shanghai, China)
  Prof Weidong Zhang (Shanghai University of Traditional Chinese Medicine, Shanghai, China)
  Prof Xiaolan Bian (School of Pharmacy and Ruijin Hospital; Shanghai Jiaotong University, Shanghai, China)
  
• Abstract:

  Introduction
  Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited treatment options, primarily relying on chemotherapy. Docetaxel (DTX) is a key chemotherapeutic agent for TNBC; however, its clinical efficacy is often hindered by drug resistance, poor solubility, and high-dose-related toxicity...

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login